按生殖阶段按 Tirzepatide 治疗的妇女的体重减轻:来自 SURMOUNT 计划的后期分析
Beverly G Tchang1, Andreea Ciudin Mihai2, Adam Stefanski3
1Department of Medicine, Division of Endocrinology, Diabetes and Metabolism, Comprehensive Weight Control Center, Weill Cornell Medicine, New York, New York, USA.
Obesity (Silver Spring, Md.)
|March 13, 2025
概括
在肥胖或超重的女性中,提尔泽帕提德显著降低了体重,腰围和腰与身高的比例,而不管更年期的阶段. 这证明了tirezepatide的存在.
科学领域:
- 内分泌学 在内分泌学.
- 代谢健康 代谢健康
- 妇女健康 妇女健康
背景情况:
- 中年妇女经常经历脂肪增加和脂肪分布的改变,特别是在更年期.
- 生殖过渡期间的荷尔蒙变化会影响身体组成和代谢健康.
研究的目的:
- 评估蒂尔泽帕提德在减轻体重和改善女性不同生殖阶段身体组成方面的疗效.
- 分析提泽帕提德对更年期前,更年期前和更年期后妇女体重,腰围和腰与身高比率 (WHtR) 的影响.
主要方法:
- 从SURMOUNT-1, -3,和 -4试验中接受提尔泽帕提德或安慰剂的妇女的后期分析.
- 参与者被追溯地按生殖阶段 (前,周,绝经后) 分类.
- 评估了体重,腰围和WHtR的变化,并实现了减肥值.
主要成果:
- 与安慰剂相比,提尔泽帕提德在所有生殖阶段 (23-26%对2-3%) 显著减少了体重.
- 实质性减少腰围和WHtR的改善观察到与tirzepatide.
- 高比例的女性 (97-98%) 通过提尔泽帕提德实现了≥5%的体重减轻,其中30-52%达到健康的WHtR (≤0.49).
结论:
- 在超重或肥胖的女性中,提尔泽帕提德治疗导致体重,腰围和WHtR显著减少,无论生殖阶段如何.
- 这些发现表明,蒂尔泽帕提德是一种有效的治疗方法,用于管理中年妇女的体重和中心脂肪.
- 药物的益处在没有2型糖尿病的更年期前,更年期前和更年期后妇女中一致.
相关概念视频
01:52Regression Toward the Mean
Regression toward the mean (“RTM”) is a phenomenon in which extremely high or low values—for example, and individual’s blood pressure at a particular moment—appear closer to a group’s average upon remeasuring. Although this statistical peculiarity is the result of random error and chance, it has been problematic across various medical, scientific, financial and psychological applications. In particular, RTM, if not taken into account, can interfere when researchers try to extrapolate results...
01:24Obesity
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in adipocytes...
01:21Drug Dosing: Obese Patients
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...